Follitropin beta biosimilar (Reliance Life Sciences)

促卵泡激素β生物类似药 (Reliance Life Sciences)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameFollitropin beta biosimilar (Reliance Life Sciences)
Drug Alias Name促卵泡激素β生物仿制药 (Reliance Life Sciences)FostiRel
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionFollicle-stimulating hormone receptor agonistsOvarian follicle stimulants
TargetsFollicle-stimulating hormone receptor
Therapy Area/IndicationsEndocrine System DiseasesInfertility, Female
Global Approved IndicationsEndocrine System DiseasesInfertility, Female
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2012/01/01
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesReliance Life Sciences
China Registration ClassN/A

Develop Information

Active CompaniesReliance Life Sciences
Inactive CompaniesN/A
Active IndicationsEndocrine System DiseasesInfertility, Female
Inactive IndicationsN/A

Other Information

ATC CodeG03GA06
Related LinksN/A